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The REstart or STop Antithrombotics
Randomised Trial (RESTART) after stroke
due to intracerebral haemorrhage:
statistical analysis plan for a randomised
controlled trial
Rustam Al-Shahi Salman1,2* , Gordon D. Murray2, Martin S. Dennis1, David E. Newby3, Peter A. G. Sandercock1,
Nikola Sprigg4, Cathie L. M. Sudlow1,2, David J. Werring5, Philip M. White6 and William N. Whiteley1
Abstract
Background: For adults surviving stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who
had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease
before the ICH, it is unclear whether starting antiplatelet therapy modifies the risks of recurrent ICH,
major haemorrhagic events, major occlusive vascular events, or a composite of all major vascular events compared
to avoiding antiplatelet therapy.
Methods/design: The REstart or STop Antithrombotics Randomised Trial (RESTART) is an investigator-led, parallel
group, open, assessor-blind, randomised trial comparing starting versus avoiding antiplatelet therapy for adults
surviving antithrombotic-associated ICH. Recruitment began on 22 May 2013 and ended on 31 May 2018. Follow-
up ended on 30 November 2018. This update to the protocol describes the statistical analysis plan (version 1.7,
finalised on 25 January 2019). Database lock and un-blinding occurred on 29 January 2019, after which the un-
masked trial statistician conducted the final analyses according to this statistical analysis plan.
Discussion: Final results of RESTART will be analysed and disseminated in May 2019.
Trial registration: ISRCTN registry 71907627. Prospectively registered on 25 April 2013.
Keywords: Secondary prevention, antiplatelet therapy, stroke, intracerebral haemorrhage, randomised controlled
trial, statistical analysis plan
Background
Patients with stroke due to spontaneous intracerebral
haemorrhage (ICH) often have past histories of vascular
disease and people who survive ICH are at risk of
vaso-occlusive events [1]. When patients develop ICH
whilst taking antithrombotic (antiplatelet or anticoagu-
lant) drugs for the prevention of vaso-occlusive disease,
these drugs are usually immediately discontinued because
of the risk of ICH growth in the 24 h after symptom onset
[2–4]. If these patients survive the early consequences
and complications of the ICH, secondary prevention of
vaso-occlusive disease is an important consideration for
many survivors [1, 3–6]. Blood pressure lowering is
effective for the prevention of stroke after ICH [7, 8].
However, it is unknown whether survivors of ICH that
occurred whilst taking antithrombotic drugs should start
or avoid antiplatelet drugs for continued secondary
prevention. A recent systematic review and meta-analysis
of observational studies of all sub-types of intracranial
haemorrhage found lower risks of ischaemic events and
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no difference in haemorrhagic events associated with anti-
platelet drug resumption [9]. Small, non-randomised ob-
servational studies restricted to patients with stroke due
to ICH have reported similar associations [10–14], but
these associations were not ‘dramatic’ so randomised con-
trolled trials (RCTs) are needed to resolve this therapeutic
dilemma [15]. However, such RCTs have not been pub-
lished [16]. Therefore, we designed the REstart or STop
Antithrombotics Randomised Trial (RESTART) to deter-
mine whether antiplatelet drugs increase the risk of recur-
rent symptomatic ICH to an extent that might outweigh
any beneficial reduction in vaso-occlusive disease [17].
Methods/Design
Trial design
The primary objective of this parallel group, open,
assessor-blind, randomised trial is to estimate the relative
and absolute effects of a policy of starting antiplatelet
drugs versus avoiding antiplatelet drugs on the risk of
recurrent symptomatic ICH after spontaneous ICH. We
intended to recruit 720 participants (based on the sample
size calculation described in the protocol [17]) and allo-
cate them 1:1 to each treatment group using a minimisa-
tion algorithm based on five variables collected beforehand,
namely (1) qualifying ICH location (lobar versus non-lobar,
based on local investigator’s interpretation of scan); (2) time
since ICH symptom onset (1–6 days, 7–30 days, > 30 days);
(3) antiplatelet drug(s) that the patient’s physician would
start if allocated (aspirin alone versus other antiplatelet
regimen, including combination treatment); (4) partici-
pant age at randomisation (< 70 years vs. 70 years or
older); and (5) predicted 6-month outcome (predicted
probability of good outcome < 0.15 vs. ≥ 0.15 [18]).
Since the primary objective of the trial is to estimate a
treatment effect, the trial does not fit into a conventional
superiority, equivalence or non-inferiority hypothesis
testing framework.
RESTART collected all participants’ diagnostic brain im-
aging (usually computed tomography (CT), but sometimes
magnetic resonance imaging (MRI) alone) that diagnosed
ICH before randomisation. An imaging sub-study was also
conducted involving brain MRI performed according to a
specific imaging protocol to test for an interaction be-
tween imaging biomarkers of cerebral small vessel disease
and the effects of antiplatelet drugs. The RESTART
imaging panel collected radiographic data from these
imaging studies, masked to treatment allocation group
[17]. The analysis of the imaging sub-studies will be
largely exploratory. The MRI sub-study will test hypo-
theses about microbleeds and explore hypotheses about
other modifiers of the effect of antiplatelet drugs. The
diagnostic CT imaging study will explore hypotheses
about modifiers of the effect of antiplatelet drugs.
Statistical interim analyses and stopping guidance
The final Data Monitoring Committee charter (version
1.6, 28 March 2014) did not specify a formal fixed
schedule of interim analyses, but allowed the Data
Monitoring Committee to advise the chair of the Trial
Steering Committee and the sponsor if there was ‘proof
beyond reasonable doubt’ that might also reasonably be
expected to influence clinical practice. Application of
this ‘overwhelming evidence’ principle makes adjust-
ment of the final level of statistical significance testing
unnecessary [19–21].
Trial population
We did not ask collaborators at participating sites to
record every patient they screened for eligibility, al-
though some sites’ standard practice was to do this
anyway, which enabled us to investigate reasons for
non-recruitment of eligible patients at these sites [22].
We asked collaborators to report and record every
patient for whom written informed consent was ob-
tained, so we will report the numbers of patients with
consent who were either randomised or not (with
reasons). Participants found to be ineligible after ran-
domisation will be quantified and categorised accord-
ing to the eligibility criteria in the protocol [17], but
they will be analysed in the treatment group to which
they were allocated. Because RESTART uses multiple
overlapping sources of ascertainment of outcomes during
follow-up [17], we will only withdraw participants from
analyses if the participant or their representative requests
complete withdrawal from all methods of follow-up after
randomisation. We will analyse data collected on the par-
ticipant up to the point of withdrawal. We will not regard
participants who change their allocated treatment as pre-
mature withdrawals. We will quantify adherence to the al-
located treatment at hospital/clinic discharge after
randomisation, and at the time of each subsequent
follow-up postal/telephone questionnaire assessment (first
done at 6 or 12months after randomisation and then an-
nually for up to 5 years). We will describe loss to
follow-up in two ways. Firstly, we will quantify the propor-
tion of patients without a complete follow-up question-
naire at each planned follow-up time point (first starting
6–12months after randomisation). Secondly, we will
quantify the sum of the total observed person-time for
each participant in the trial as a proportion of the sum
of their total potential person-time until the last
planned trial follow-up questionnaire for that partici-
pant [23].
Analysis populations
All analyses will follow the ‘intention-to-treat’ principle
in order to fully preserve the benefit of randomisation.
The intention-to-treat population will comprise all
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participants who have been randomised in RESTART,
regardless of whether they were subsequently deemed
ineligible after independent review of their diagnostic
brain imaging. We will include all randomised partici-
pants in the analysis (irrespective of whether they adhere
to the allocated treatment), all retained in the group to
which they were allocated (i.e. ‘as-randomised’). How-
ever, in the brain imaging studies within RESTART,
imaging may (1) not have proceeded despite consent
being obtained; (2) not have been provided; (3) have
been undertaken but may have contravened the required
protocol; (4) have been undertaken, but was degraded by
motion artefact; or (5) have demonstrated that the
patient was ineligible for inclusion in RESTART (which
precluded collection of ratings by the RESTART Imaging
Panel). Therefore, patients will be included in the CT
imaging study and the MRI sub-study datasets if their
pre-randomisation brain imaging was readable and
confirmed their eligibility for RESTART.
Baseline characteristics
We will summarise the following baseline characteristics
overall and by treatment group:
 The covariates used in the minimisation algorithm
(qualifying ICH location, time since ICH symptom
onset, antiplatelet drug(s) that patient’s physician
would start if allocated, participant age at
randomisation, predicted 6-month outcome)
 Sex
 Ethnicity
 Functional status
 Modified Rankin scale (mRS) score
 Co-morbidities
 Antithrombotic drugs taken before ICH
 Timing of key events (symptom onset to
randomisation, symptom onset to earliest imaging
study, earliest imaging study to randomisation,
symptom onset to sub-study MRI (if applicable), and
sub-study MRI to randomisation (if applicable))
 Characteristics of the ICH and brain on diagnostic
imaging and sub-study MRI (if applicable)
– The RESTART imaging panel’s report of CT
diagnostic imaging will describe the baseline
characteristics of the trial population’s brains
(e.g. old vascular lesions, periventricular
lucencies and atrophy) and ICH (e.g. location,
intraventricular extension, subarachnoid
extension, ICH volume and finger-like projec-
tions [24])
– The RESTART imaging panel’s report of MRI
sub-study protocol-compliant imaging will de-
scribe the baseline characteristics of the partici-
pants’ brains (e.g. brain microbleed presence/
location and burden, old infarcts or haemor-
rhages, superficial siderosis, white matter hyper-
intensities, and atrophy) and ICH (e.g. location,
intraventricular extension, subarachnoid exten-
sion, and ICH volume). In the MRI sub-study,
the focus of our hypothesis will be on testing
whether the presence, number or location of brain
microbleeds modifies the effect of antiplatelet
drugs on the primary outcome, adjusted for the
same covariates used in the primary analysis of the
entire RCT. For dichotomous analysis, the num-
ber of brain microbleeds will be split as 0 or 1
versus 2 or more and for categorical analysis
the split will be 0 or 1 versus 2 to 4 versus 5
or more. Brain microbleed location will be
grouped as strictly lobar versus other
Outcomes
We collected symptomatic outcomes during follow-up
without explicit definitions in order to minimise the
complexity of the reporting process for participants,
their general practitioners, carers and investigators.
During the outcome event adjudication process, we were
guided by the principles and definitions described by the
Standardised Data Collection for Cardiovascular Trials
Initiative [25]. We classify events as fatal (if they were
followed by death within 30 days) or non-fatal (if they
were not followed by death within 30 days).
 Fatal or non-fatal radiographically or pathologically
proven recurrent symptomatic ICH. We define this
as the abrupt onset of headache, altered level of con-
sciousness, or focal neurological deficit, anatomically
referable to a focal collection of blood predomi-
nantly located within the brain parenchyma
(diagnosed on brain imaging or at autopsy), which
was not attributable to prior trauma or haemor-
rhagic transformation of an ischaemic stroke. This
also applies when neurological deterioration occurs
with radiographic or pathological evidence of ICH
volume growth early after the qualifying ICH (due
to either haematoma expansion or re-bleeding)
 Symptomatic spontaneous or traumatic extradural
haemorrhage, subdural haemorrhage, subarachnoid
haemorrhage, or intraventricular haemorrhage (not
accompanying spontaneous ICH)
 Symptomatic major extracranial haemorrhage
(requiring transfusion or endoscopic treatment or
surgery, or resulting in death within 30 days, i.e.
Bleeding Academic Research Consortium definition
for bleeding types 3–5 [26])
 Transient ischaemic attack
 Ischaemic stroke
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 Acute coronary syndrome (restricted to STEMI and
non-STEMI myocardial infarction, but not hospital-
isation for unstable angina)
 Peripheral arterial occlusion
 Mesenteric ischaemia
 Retinal arterial occlusion
 Deep vein thrombosis
 Pulmonary embolism
 Revascularisation procedures (carotid, percutaneous
coronary intervention or peripheral arterial
intervention)
 Sudden cardiac death with symptoms suggestive of
myocardial ischaemia (type 3) or evidence of
arrhythmia (i.e. sudden cardiac death [25])
 Symptomatic stroke of uncertain sub-type
– Non-fatal stroke, with brain imaging performed
too late to distinguish ICH from cerebral
infarction
– Rapidly fatal stroke, but without radiographic or
pathological confirmation
 Deaths not due to fatal major vascular events above
– Other cardiovascular deaths (e.g. due to heart
failure, cardiovascular procedures, cardiovascular
haemorrhage)
– Non-cardiovascular deaths
– Deaths of undetermined cause
 Annual ratings of participant function completed by
participants or their carer using the simplified mRS
postal questionnaire [27, 28], or structured
telephone interview with non-responders to the pos-
tal questionnaire [29]
The primary outcome is fatal or non-fatal radio-
graphically or pathologically proven recurrent symp-
tomatic ICH. The two key secondary outcomes are a
composite of all major haemorrhagic events and a
composite of all major vaso-occlusive events (inclu-
ding revascularisation procedures):
 The composite secondary outcome of ‘all major
haemorrhagic events’ includes the following fatal or
non-fatal symptomatic events (that are ‘major’ be-
cause of their usual need for hospitalisation and in-
fluence on outcome and antithrombotic treatment):
– Radiographically or pathologically proven
recurrent symptomatic ICH (the primary
outcome)
– Other forms of symptomatic spontaneous or
traumatic intracranial haemorrhage, including
radiographically or pathologically proven
spontaneous or traumatic extradural haemorrhage,
subdural haemorrhage, subarachnoid haemorrhage
or intraventricular haemorrhage (not
accompanying spontaneous ICH)
– Extracranial haemorrhage at any site requiring
transfusion/endoscopic treatment/surgery, or
resulting in death
 The composite secondary outcome of ‘all major
vaso-occlusive events (including revascularisation
procedures)’ includes the following fatal or non-fatal
symptomatic events (that are ‘major’ because of
their usual need for hospitalisation and influence on
outcome and antithrombotic treatment; therefore,
we will not include transient ischaemic attack or ret-
inal artery occlusion) or revascularisation
procedures:
– Fatal or non-fatal vaso-occlusive events, including
ischaemic stroke, acute coronary syndrome, mes-
enteric ischaemia or peripheral arterial occlusion,
deep vein thrombosis, or pulmonary embolism
– Carotid, coronary or peripheral arterial
revascularisation procedures
The composite secondary outcome of ‘all major hae-
morrhagic or vaso-occlusive events’ combines the two com-
posites defined above. For completeness, the corresponding
analysis will also be performed for each composite outcome
event proposed in the trial protocol. The interpretation of
the trial findings will respect this pre-specified hierarchy of
primary outcome, key secondary outcomes and other sec-
ondary outcomes, and no formal adjustment will be made
to significance levels to allow for multiplicity.
We will summarise the total numbers of the primary
and secondary outcomes during follow-up, as well as the
number of first events of each type during follow-up,
overall and by treatment group.
Serious adverse events are reported in RESTART if
they are neither an outcome event nor an expected
complication of stroke. Serious adverse events will be
grouped by body system and for each event and each
grouped set of events, we will quantify the number of
events and the number of individuals experiencing at
least one such event per allocated treatment group.
We will report adherence (at last follow-up before the
occurrence of the first outcome event) to the allocated
antiplatelet treatment strategy (start vs. avoid antiplatelet
drugs) and use of anticoagulant drugs descriptively per
treatment group at discharge and at each annual
follow-up. Because blood pressure (BP) control is a po-
tential confounder of the frequency of the primary out-
come, the use of BP-lowering drugs at discharge after
randomisation and at each annual follow-up will be re-
ported (along with a summary of the available BPs of
participants by treatment group).
Any change, divergence or departure from the trial
design or procedures defined in the protocol or Good
Clinical Practice are identified and recorded as a
deviation (if it does not significantly affect a participant’s
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rights, safety or well-being, or trial outcomes), or a
violation (if the deviation may potentially significantly
impact the completeness, accuracy and/or reliability of the
trial data or that may significantly affect a patient’s rights,
safety or well-being). We will list all protocol deviations
and violations, but no formal statistical testing will
be performed.
Methods of analysis
In general terms, we will present categorical data using
counts and percentages, continuous variables using the
mean, median, standard deviation (SD), minimum, max-
imum, inter quartile points at 25% and 75% (Q1 and Q3),
and number of patients with an observation (n). We will
estimate the survival function per treatment group using a
Kaplan–Meier survival analysis of time to first outcome
event during all available follow-up after randomisation.
We will censor follow-up at death (unrelated to an out-
come event), last available follow-up or voluntary with-
drawal from the trial. We will compare the survival
function in the two trial arms using a Cox proportional
hazards regression model, adjusting for all the covariates
included in the minimisation algorithm (qualifying ICH lo-
cation of lobar versus non-lobar; time since ICH symptom
onset of 1–6 days versus 7–30 days versus over 30 days; an-
tiplatelet drug(s) that the patient’s clinician would start if al-
located (aspirin alone vs. any other regimen); participant’s
age at randomisation (< 70 years vs. ≥ 70 years); predicted
probability of a good 6-month outcome (< 0.15 vs. ≥ 0.15)),
and presenting the result as an estimated adjusted hazard
ratio with its corresponding 95% CI. We will also report the
unadjusted estimate of the hazard ratio and its correspond-
ing 95% CI, together with the result of the logrank test. We
will estimate the absolute difference in event rates at 1, 2, 3
and 4 years from the Kaplan–Meier analysis.
We will conduct two exploratory sensitivity analyses of
our primary analysis, by adding the following secondary
outcomes to the primary outcome in the following
order, to account for the possibility that some fatalities
and non-fatal neurological events without adequate
investigation may be recurrent ICH:
 Symptomatic stroke of uncertain sub-type
 Deaths of undetermined cause
We will conduct a sensitivity analysis of the second-
ary outcomes to reflect the cumulative incidence of
major haemorrhagic or vaso-occlusive events, using
re-randomisation tests [30].
We will perform sub-group analyses for the primary
outcome and the key secondary outcomes including (1)
all major haemorrhagic events, (2) all major vaso-occlu-
sive events (including revascularisation procedures), and
(3) the composite of all major haemorrhagic or
vaso-occlusive events. We will analyse heterogeneity of
treatment effect between sub-groups using statistical tests
of interaction. These analyses will be performed by inclu-
ding an interaction term between treatment group and
the relevant covariate in the Cox proportional hazards
regression model. Time since ICH will be dichotomised in
view of the distribution of outcomes in the whole trial
dataset. Should any of these adjusted regression models
fail to converge, then the corresponding unadjusted
analysis will be reported instead. We have specified a
priori the following dichotomous sub-groups for the
primary analysis:
 The five covariates used in the minimisation
algorithm
– Qualifying ICH location (lobar vs. non-lobar)
– Time since ICH symptom onset (two subgroups
will be defined based on the time from onset
being above or below the median time observed
in the trial)
– Antiplatelet drug(s) that the patient’s clinician
would start if allocated (aspirin alone vs. any
other regimen)
– Participant’s age at randomisation (< 70 years vs.
≥ 70 years)
– Predicted probability of a good 6-month outcome
(< 0.15 vs. ≥ 0.15)
 Pre-ICH antithrombotic drug regimen (antiplatelet
vs. anticoagulant)
 History of atrial fibrillation documented as a co-
morbidity at randomisation (yes vs. no)
We will perform a separate analysis for each annual
assessment of the mRS score. The analysis at year ‘x’ will
be restricted to participants who were randomised at
least ‘x’ years prior to study close, to avoid including
early deaths in the relevant follow-up year when the
corresponding surviving recruits would not have had the
potential to be assessed. The analysis will comprise a
tabulation of mRS by randomised group, with the formal
analysis being based on a Mann–Whitney test. Parti-
cipants’ type of domicile will be described as categorised
on the discharge form and each annual participant
questionnaire.
Statistical principles
We will use available data and not impute data with
regard to missing values or withdrawals. We will not
perform formal statistical tests of baseline characteristics
or adherence by treatment group. All applicable statis-
tical tests will be two-sided and will be performed using
a 5% significance level, leading to 95% (two-sided) confi-
dence intervals, unless otherwise specified. We will
assess the proportional hazards assumption graphically; if
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there is strong evidence of violation of the assumption,
the impact on the analysis will be assessed by comparing
the results of the pre-specified analysis with the results
obtained using the restricted survival time approach [31].
Statistical software
The un-blinded trial statistician at the Edinburgh
Clinical Trials Unit (ECTU) will perform the statistical
programming and analysis to produce all summary tables
and figures using the statistical package SAS (v9.3 or a
more recent version).
Quality control
Before database lock and un-blinding, a full statistical re-
port will be produced based on dummy randomisation
codes to allow for checking of the data and the proposed
summaries/analyses. Isolated data errors detected in the
database as a result of quality control checks that are
deemed significant will be submitted for enquiry to the
trial manager or designee. Systematic data errors in the
data reporting will be investigated further; the data will
be corrected if necessary, and the appropriate table then
re-checked. A random selection of unique analysis and
summary tables will be checked using manual methods
(i.e. comparison of results in the table to results cal-
culated by a calculator, spreadsheet, database output or
any alternative summarisation tool). Checks of statistical
analyses will be performed by peer review of program
code, log and output. Additionally, the primary out-
comes analysis will be replicated independently by a
second statistician.
Administrative information
The published RESTART protocol reflected version
7.0, created on 23 December 2015 [17]. The final
amendment that was made to the protocol (version
8.0, created on 19 September 2017) was an update
to the reference safety information used for clopi-
dogrel. Standard operating procedures produced by
the sponsor (http://www.accord.scot/research-ac-
cess/resources-researchers/sop) guided trial con-
duct. ECTU standard operating procedures guided
the content and format of the final version of the
statistical analysis plan (https://www.ed.ac.uk/usher/
edinburgh-clinical-trials/supporting-trials/govern-
ance/standard-operating-procedures). This published
statistical analysis plan complies with relevant
reporting standards and reflects version 1.6 of the
statistical analysis plan (see Additional files 1 and
2), which was written and signed by the blinded
trial statistician (GDM), was counter-signed by the
chief investigator (RA-SS), and included a history of
revisions and their timings [32]. The definitions of
outcome events have been expanded upon in this
published version of the statistical analysis plan.
The funder and sponsor did not require a data
management plan, but plans for data sharing were
described in the published protocol [17]. The spon-
sor delegated responsibility for maintaining the trial mas-
ter file to the trial management group (2013/W/NEU/04/
TMF), who keep it in DataStore, which is the University
of Edinburgh’s file store for active research data (https://
www.ed.ac.uk/information-services/research-support/re-
search-data-service/working-with-data/data-storage). The
un-blinded trial statistician maintains a paper copy of the
statistical master file, which is held securely within ECTU.
Discussion
This published version of the final RESTART statis-
tical analysis plan, which we have reported according
to recent guidelines [32], describes details of our ap-
proach to describing the trial population, the statis-
tical principles we will apply to the analysis
population, and the analyses we will undertake. We
submitted this statistical analysis plan before the end
of follow-up and data lock, with one minor modifica-
tion after the end of follow-up but before database
lock and un-blinding, in view of the distribution of
outcomes in the entire analysis population. We standar-
dised outcome event definitions before un-masking the
trial steering committee to the results [25, 26]. This
report should provide reassurance about protection of
the trial from selective outcome reporting and data-
driven analyses.
The results of this trial will help to estimate, for the
first time, the effects of antiplatelet drugs on recurrent
ICH. This will provide information about the likely net
effects of antiplatelet drugs after ICH, and whether a
larger RCT will be required to estimate effects on all
major vascular events or functional outcome.
Trial status
Recruitment ended on 31 May 2018. Follow-up ended
on 30 November 2018. Data lock occurred on 29 January
2019, after which the un-blinded trial statistician con-
ducted the final analyses according to this statistical
analysis plan. The current protocol is version 8.0,
created 19 September 2017 (all protocol updates since
version 3.0, created 1 February 2013, which was
implemented before randomisation began, have been
approved by the sponsor and research ethics com-
mittee and also communicated to investigators and
trial registries). This manuscript is based on version
1.7 of the RESTART statistical analysis plan, finalised
on 25 January 2019.
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Additional file 1: SAP checklist. Reporting checklist: recommended items
to address in a clinical trial Statistical Analysis Plan [32]. (DOCX 38 kb)
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